Betamethasone Sodium Phosphate
FDA-approved product (injectable, injection), marketed as Betamethasone Sodium Phosphate, Celestone.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 1 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Airway obstruction
- Eye inflammation
- Hemorrhoid
- Nasal congestion
- Ulcerative colitis
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Corticosteroids acting locally; Corticosteroids; Corticosteroids, potent (group iii); Corticosteroids, potent, other combinations; Glucocorticoids
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.
AI-predicted activity
AI prediction · nothing measured- MRSA56.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli36.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae32.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis31.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Betamethasone Sodium Phosphate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Levocabastine HydrochlorideExisting use: Eye allergy, Nasal congestion49.5% AI-predicted activityagainst E. coli5 registered studies
- SaquinavirExisting use: HIV infection, HIV-1 infection, Viral disease49.4% AI-predicted activityagainst E. coli50+ registered studies
- Ibrexafungerp CitrateExisting use: Vulvovaginal candidiasis49.4% AI-predicted activityagainst E. coliNo documented evidence found
- Mobocertinib SuccinateExisting use: Neoplasm, Non-small cell lung carcinoma49.2% AI-predicted activityagainst E. coliNo documented evidence found
- SparsentanExisting use: IGA glomerulonephritis49.2% AI-predicted activityagainst E. coli11 registered studies
- Epinastine HydrochlorideExisting use: Allergic conjunctivitis, Allergic disease, Eye allergy49.0% AI-predicted activityagainst E. coli10 registered studies
- Omidenepag IsopropylExisting use: Ocular hypertension, Open-angle glaucoma49.0% AI-predicted activityagainst E. coli1 registered study
- LesinuradExisting use: Gout, Hyperuricemia49.0% AI-predicted activityagainst E. coli22 registered studies
- Imatinib MesylateExisting use: Acute lymphoblastic leukemia, B-cell acute lymphoblastic leukemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive and 7 more48.9% AI-predicted activityagainst E. coli50+ registered studies
- Prucalopride SuccinateExisting use: Constipation, Constipation disorder48.9% AI-predicted activityagainst E. coli7 registered studies
- FamciclovirExisting use: Eye infection, Genital herpes, Herpes Labialis and 3 more48.8% AI-predicted activityagainst E. coli25 registered studies
- AbemaciclibExisting use: Breast cancer, Breast carcinoma, Breast neoplasm and 3 more48.7% AI-predicted activityagainst E. coli50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Efficacy of Micro-Pulse Steroid Therapy as Induction Therapy in Patients With Polymyalgia Rheumatica
NCT00982332 · start 2010-03
Registered record
- Registry ID
- NCT00982332
- Conditions
- Polymyalgia Rheumatica
- Interventions
- Betamethasone; isotonic sodium chloride solution (placebo)
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Unknown
- Start
- 2010-03
- Completion
- 2012-03
- Enrolment
- 20
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPolymyalgia RheumaticaInterventionBetamethasone; isotonic sodium chloride solution (placebo)PhaseNot applicableRegistry statusUnknownComparison of 2 Doses of Corticosteroid Subacromial Injections for the Treatment of Painful Shoulder
NCT00914836 · start 2009-06
Registered record
- Registry ID
- NCT00914836
- Conditions
- Tendonitis; Bursitis
- Interventions
- Betamethasone Sodium Phosphate; 1 cc - Betamethasone Sodium Phosphate; 2 cc - Betamethasone Sodium Phosphate
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Withdrawn
- Start
- 2009-06
- Completion
- 2010-04
- Enrolment
- 0
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionTendonitis; BursitisInterventionBetamethasone Sodium Phosphate; 1 cc - Betamethasone Sodium Phosphate; 2 cc - Betamethasone Sodium PhosphatePhaseNot applicableRegistry statusWithdrawnEvaluation of Diprospan Injection to the Knee on Rehabilitation of Patients After TKR of the Contralateral Knee
NCT00542139 · start 2007-12
Registered record
- Registry ID
- NCT00542139
- Conditions
- Osteoarthritis
- Interventions
- Betamethasone; Bupivocaine
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2007-12
- Completion
- 2008-11
- Enrolment
- 50
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionOsteoarthritisInterventionBetamethasone; BupivocainePhasePhase 4Registry statusCompletedORTHOVISC Shoulder Osteoarthritis Study
NCT00436969 · start 2006-12
Registered record
- Registry ID
- NCT00436969
- Conditions
- Glenohumeral Osteoarthritis
- Interventions
- Orthovisc; Control
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2006-12
- Completion
- 2011-08
- Enrolment
- 274
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionGlenohumeral OsteoarthritisInterventionOrthovisc; ControlPhasePhase 3Registry statusCompletedBetamethasone to Control Postoperative Pain in Emergency Endodontic Care
NCT02865746 · start 2004-07
Registered record
- Registry ID
- NCT02865746
- Conditions
- Pain
- Interventions
- Bethametasone; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2004-07
- Completion
- 2005-12
- Enrolment
- 120
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPainInterventionBethametasone; PlaceboPhaseNot applicableRegistry statusCompleted